IPCA LABORATORIES Financial Statement Analysis
|
||
|
The Revenues of IPCA LABORATORIES have increased by 16.11% YoY .
The Earnings Per Share (EPS) of IPCA LABORATORIES has increased by 54.68 % YoY. |
||
IPCA LABORATORIES Last 5 Annual Financial Results
[BOM: 524494|NSE : IPCALAB]
| Consolidated | Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 |
|---|---|---|---|---|---|
| Revenues | ₹8,897 Cr | ₹7,662 Cr | ₹6,204 Cr | ₹5,797 Cr | ₹5,395 Cr |
| Expenses | ₹7,226 Cr | ₹6,398 Cr | ₹5,301 Cr | ₹4,539 Cr | ₹3,914 Cr |
| Operating Profit (Excl OI) | ₹1,671 Cr | ₹1,264 Cr | ₹903 Cr | ₹1,258 Cr | ₹1,481 Cr |
| Other Income | ₹151 Cr | ₹184 Cr | ₹152 Cr | ₹122 Cr | ₹129 Cr |
| Interest | ₹88 Cr | ₹141 Cr | ₹48 Cr | ₹11 Cr | ₹12 Cr |
| Depreciation | ₹398 Cr | ₹357 Cr | ₹262 Cr | ₹232 Cr | ₹209 Cr |
| Profit Before Tax | ₹1,131 Cr | ₹843 Cr | ₹745 Cr | ₹1,136 Cr | ₹1,389 Cr |
| Profit After Tax | ₹788 Cr | ₹529 Cr | ₹492 Cr | ₹911 Cr | ₹1,149 Cr |
| Consolidated Net Profit | ₹738 Cr | ₹547 Cr | ₹471 Cr | ₹884 Cr | ₹1,140 Cr |
| Earnings Per Share (Rs) | ₹44.98 | ₹29.08 | ₹21.57 | ₹18.58 | ₹34.85 |
| PAT Margin (%) | 12.35 | 8.81 | 6.87 | 7.88 | 15.63 |
| ROE(%) | 15.88 | 11.86 | 8.70 | 8.70 | 17.92 |
| ROCE(%) | 19.41 | 15.27 | 13.10 | 11.71 | 20.46 |
| Total Debt/Equity(x) | 0.09 | 0.19 | 0.22 | 0.25 | 0.14 |
Key Financials |
||
| Market Cap | : | ₹ 49,466.4 Cr |
| Revenue (TTM) | : | ₹ 10,479.0 Cr |
| Net Profit(TTM) | : | ₹ 1,487.8 Cr |
| EPS (TTM) | : | ₹ 58.6 |
| P/E (TTM) | : | 33.2 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| IPCA LABORATORIES | 1.2% | 0.2% | 53.1% |
| SUN PHARMACEUTICAL INDUSTRIES | 2.7% | 1.4% | 4.3% |
| DIVIS LABORATORIES | 4.5% | 6.3% | 50.8% |
| TORRENT PHARMACEUTICALS | 1.8% | -1.3% | 31.4% |
| CIPLA | 1.6% | 4.4% | -9.1% |
| DR REDDYS LABORATORIES | 0.8% | 12.5% | 14.1% |
| MANKIND PHARMA | 1.1% | 1.2% | 3.6% |
| LUPIN | -1.1% | -2.3% | 3.6% |
| ZYDUS LIFESCIENCES | -3.8% | 3.1% | 20.7% |
IPCA LABORATORIES Revenues
[BOM: 524494|NSE : IPCALAB]
| Y-o-Y | 16.11 % |
| 5 Yr CAGR | 13.32 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2026 | ₹8,897 Cr | 16.11 | |
| Mar2025 | ₹7,662 Cr | 23.50 | |
| Mar2024 | ₹6,204 Cr | 7.03 | |
| Mar2023 | ₹5,797 Cr | 7.45 | |
| Mar2022 | ₹5,395 Cr | - | |
IPCA LABORATORIES Operating Profit
[BOM: 524494|NSE : IPCALAB]
| Y-o-Y | 32.16 % |
| 5 Yr CAGR | 3.05 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2026 | ₹1,671 Cr | 32.16 | |
| Mar2025 | ₹1,264 Cr | 39.94 | |
| Mar2024 | ₹903 Cr | -28.18 | |
| Mar2023 | ₹1,258 Cr | -15.10 | |
| Mar2022 | ₹1,481 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | 13.82 % |
| 5 Yr CAGR | -9.06 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2026 | 18.78% | 13.82 | |
| Mar2025 | 16.5% | 13.32 | |
| Mar2024 | 14.56% | -32.90 | |
| Mar2023 | 21.7% | -20.98 | |
| Mar2022 | 27.46% | - | |
IPCA LABORATORIES Profit After Tax
[BOM: 524494|NSE : IPCALAB]
| Y-o-Y | 34.77 % |
| 5 Yr CAGR | -10.31 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2026 | ₹738 Cr | 34.77 | |
| Mar2025 | ₹547 Cr | 16.13 | |
| Mar2024 | ₹471 Cr | -46.69 | |
| Mar2023 | ₹884 Cr | -22.45 | |
| Mar2022 | ₹1,140 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | 40.18 % |
| 5 Yr CAGR | -5.72 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2026 | 12.35 % | 40.18 | |
| Mar2025 | 8.81 % | 28.24 | |
| Mar2024 | 6.87 % | -12.82 | |
| Mar2023 | 7.88 % | -49.58 | |
| Mar2022 | 15.63 % | - | |
IPCA LABORATORIES Earnings Per Share (EPS)
[BOM: 524494|NSE : IPCALAB]
| Y-o-Y | 54.68 % |
| 5 Yr CAGR | 6.59 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2026 | ₹45 | 54.68 | |
| Mar2025 | ₹29 | 34.82 | |
| Mar2024 | ₹22 | 16.09 | |
| Mar2023 | ₹19 | -46.69 | |
| Mar2022 | ₹35 | - | |
IPCA LABORATORIES Return on Capital Employed (ROCE)
[BOM: 524494|NSE : IPCALAB]
| Y-o-Y | 27.11 % |
| 5 Yr CAGR | -1.31 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2026 | 19.41% | 27.11 | |
| Mar2025 | 15.27% | 16.56 | |
| Mar2024 | 13.1% | 11.87 | |
| Mar2023 | 11.71% | -42.77 | |
| Mar2022 | 20.46% | - | |
IPCA LABORATORIES Share Price vs Sensex
| Current Share Price | : | ₹1,949.8 |
| Current MarketCap | : | ₹ 49,466.4 Cr |
| Updated EOD on | : | Nov 05,2026 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| IPCA LABORATORIES | 1.2% |
0.2% |
53.1% |
| SENSEX | 7% |
9.6% |
-6.7% |
IPCA LABORATORIES related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE 250 LARGEMIDCAP INDEX | 6.2% | 6.5% | -3.6% |
| BSE 500 | 5.8% | 5.7% | -3.3% |
| BSE 1000 | 5.6% | 5% | -2.8% |
| BSE 150 MIDCAP INDEX | 4.8% | 2.2% | -0.6% |
| BSE 400 MIDSMALLCAP INDEX | 4.1% | 1.3% | -0.8% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY MIDSMALL INDIA CONSUMPTION | 6.4% | 4% | -8.5% |
| NIFTY 500 | 5.9% | 5.7% | -3% |
| NIFTY LARGEMIDCAP 250 | 5.8% | 5.2% | -1.9% |
| NIFTY TOTAL MARKET | 5.7% | 5.3% | -2.7% |
| NIFTY500 MULTICAP 50:25:25 | 5.2% | 4.4% | -1.7% |
You may also like the below Video Courses
FAQ about IPCA LABORATORIES Financials
How the annual revenues of IPCA LABORATORIES have changed ?
The Revenues of IPCA LABORATORIES have increased by 16.11% YoY .
How the Earnings per Share (EPS) of IPCA LABORATORIES have changed?
The Earnings Per Share (EPS) of IPCA LABORATORIES has increased by 54.68 % YoY .
Check out Intrinsic Value of Peers of IPCA LABORATORIES
Compare Stock Analytics of Peers of IPCA LABORATORIES
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs
